BRAF and plasma cell myeloma: Trametinib (Mekinist®, developed by Japan Tobacco, Inc. and GlaxoSmithKline) and bortezomib (Velcade®, developed by Millennium Pharmaceuticals, Inc.)have already been approved and clinically used for melanomas harbouring BRAF V600 mutations and refractory multiple myelomas, respectively39, 40, 41, 42, 43.